JEREMY PURSER: Open Payments
NPI 1053974659 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,632 in 124 payments from 19 companies in 2025. Trend: 2023 $2,130 · 2024 $2,818 · 2025 $2,632
Food & beverage: $2,537Education: $95
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 14 | $387 |
| Janssen Biotech, Inc. | 13 | $355 |
| Regeneron Healthcare Solutions, Inc. | 9 | $256 |
| Galderma Laboratories, L.P. | 16 | $181 |
| Lilly USA, LLC | 8 | $173 |
| GENZYME CORPORATION | 11 | $161 |
| Arcutis Biotherapeutics, Inc. | 9 | $154 |
| Organon LLC | 8 | $148 |
| Novartis Pharmaceuticals Corporation | 6 | $123 |
| Amgen Inc. | 5 | $111 |
Products named: Bimzelx, TREMFYA, DUPIXENT, NEMLUVIO, Zoryve, TALTZ, COSENTYX, OTEZLA.
Industry payments across TX — which companies pay providers there.
